Checkmate Pharmaceuticals (CMPI) Environmental, Social & Governance (ESG) Data

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Environment Environmental Environmental Protection Extreme Weather Intensity Materials Nature Offset Package Packaging Pandemic Raw Materials Toxic Waste Access Benefits Black California Consumer Privacy Act Charitable Community Customer Cyber Data Privacy Data Security Death Diversity Diversity and Inclusion Drug Pricing Employee Employee Retention Gender General Data Protection Regulation Health and Safety Health Care Healthcare Hire Hiring Human Capital Human Resources Incident Injuries Injury Minority Privacy Product Safety Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skills Social Society Stakeholder Supplier Supply Chain Training Union Volunteer Women Workers Workforce Activist Antitrust Assessment Assurance Attorney General Attorneys General Audit Classified Commitment Conflict of Interest Corporate Governance Department of Ethics Executive Compensation Expert Fraud Goals Hedging Incentive Incentivize Independence Independent Innovation Innovative Investigation Lawsuit Leadership Litigation Long-term Majority Mission Oversee Oversight Plaintiff Proxy Access Proxy Contest Purpose Quality Standard R&D Recoup Reputation Reputational Research and Development Responsibility Responsible Special Meeting Stewardship Strategy Sustainable Targets Tax Transparency Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

The 2021 Annual Meeting of Stockholders (the “Annual Meeting”) of Checkmate Pharmaceuticals, Inc. (the “Company”) was held on June 16, 2021. Proxies were solicited pursuant to the Company’s proxy statement filed on April 27, 2021 with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended. The number of shares of the Company’s common stock, $0.0001 par value per share (“Common Stock”), entitled to vote at the Annual Meeting was 21,625,891. The number of shares of Common Stock present or represented by valid proxy at the Annual Meeting was 14,089,054, representing a majority of the shares of Common Stock entitled to vote at the Annual Meeting. Each share of Common Stock was entitled to one vote with respect to matters submitted to the Company’s stockholders at the Annual Meeting.
At the Annual Meeting, the Company’s stockholders were asked (i) to elect two Class I directors to the Company’s Board of Directors (the “Board”), each to hold office until the 2024 annual meeting of stockholders and until their successor is duly elected and qualified, or until their earlier resignation or removal, and (ii) to ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.
The voting results reported below are final.
Proposal 1 – Election of Directors
Michael Powell, Ph.D. and Nilesh Kumar, Ph.D., were duly elected to the Company’s Board as Class I directors. The results of the election were as follows:

NOMINEE

Michael Powell, Ph.D.	12,465,032	400,688	411,957	811,377
Nilesh Kumar, Ph.D.	12,620,635	245,085	411,957	811,377

Proposal 2 – Ratify the Appointment of Independent Registered Public Accounting Firm
The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021 was ratified. The results of the ratification were as follows:


	FOR		AGAINST		ABSTAIN
NUMBER		14,061,659		25,185		2,210